

Commentary

Global equities started the year lower as violent moves in highly shorted retail stocks led to volatility and de-risking in other areas of the market (+0.1% following weakness in the AUD). Whilst some cyclical sectors outperformed, led by Energy and Consumer Discretionary, investors continued to exhibit a preference for momentum and growth over low multiple - or value - stocks, with Communications Services and Healthcare also outperforming.

Markets started the month higher as the global roll out of vaccinations and prospects of further fiscal and monetary stimulus outweighed concerns about virus driven restrictions. However, a group of heavily shorted stocks in the US rallied strongly as a community of retail investors coordinated a short squeeze, forcing investors to de-gross their portfolios. US equities performed in line. President Biden continues to push a \$1.9tn stimulus package including a \$1,400 payment to individuals, supported by a slim Democratic Senate majority following success in the Georgia Senate race. European equities (-0.9%) lagged on vaccine distribution concerns and softer than expected economic data.

Emerging Markets outperformed (+3.7%) led by China (+6.9%) as strong economic momentum on a rebound in global growth and optimism of reduced US/China tensions led to an acceleration of southbound inflows after a period of underperformance.

Elsewhere, Brent Crude rallied strongly on demand optimism for a third month (+6.3% in USD) and Gold (-1.3% in USD) retreated.

Key contributors to performance included:

- Connectivity/Compute cluster, notably TSMC which lifted its medium term growth targets due to strong demand for leading edge semiconductor manufacturing in key end markets and market share gains with key customers.
- Online services Emerging Markets (EM), notably Tencent which entered into a tech partnership with automaker Geely to, amongst other things, develop smart vehicle cockpits and autonomous driving technology.
- Industrials, notably Siemens, which pre-announced another strong result driven by Digital Industries (automation, including hardware and software) with better than expected profitability.

Key detractors to performance included:

- Infrastructure/Property DM, notably EDF, as a decision regarding the company's new regulation and restructure has been delayed.
- Consumer Cyclical EM including KB Financial, as performance of financials and travel exposures consolidated as COVID-19 data deteriorated into 2020 year end.
- Online Services DM, notably Facebook, on cautious guidance around growth in the second half of 2021 and uncertainty around Apple handset users being able to 'opt out' of data sharing. The impact is likely to be small and expected to be more than offset by continued healthy engagement trends and opportunities to increase monetisation.

Net performance (%)

	Fund	Benchmark	Difference
1 month	-0.2	0.1	-0.3
3 month	9.3	7.1	2.2
Year to date	-0.2	0.1	-0.3
1 year	4.8	2.1	2.7
Inception p.a.	7.7	11.7	-4.0
Inception	18.1	28.2	-10.1

Past performance is not a reliable indicator of future performance. Returns are calculated net of applicable fees, costs and taxes.

Top 10 equity longs (%)

Name	Country	Weight
Facebook	United States	3.6
Microsoft	United States	3.3
Siemens	Germany	3.1
Taiwan Semiconductor	Taiwan	2.9
Ping An Insurance	China/HK	2.8
Volkswagen	Germany	2.6
Samsung Electronics	Korea	2.6
Tencent	China/HK	2.6
HDFC Bank	India	2.3
Merck	United States	2.3


iNAV tickers

	Unit Price	iNAV
Bloomberg	AGX1.AU Equity	AGFLIV Index
Thomson Reuters	AGX1.AX	AGFLOFV-SOLA
IRESS	AGX1.AXW, AGX1.CXA	AGX1IV

Fund facts

Characteristics	
Investment manager	Antipodes
Inception date	5 November 2018
Benchmark	MSCI All Country World Net Index in AUD
Management fee	1.10% p.a.
Performance fee	15% of net return in excess of benchmark
Distribution	Annual, 30 June
Unit valuation	Sydney business day
Asset value	
Fund AUM	\$22m
Strategy AUM	\$2,594m
Asset Value (NAV)	5.7070

Sector exposure¹ (%)




¹ Antipodes classification

Asset allocation³

	Equities - Long	Other - Long
Weight (%)	88.5	0.5
Count	58	1
Avg. weight (%)	1.5	0.5
Top 10 (%)	28.1	-
Top 30 (%)	64.0	-

³ Call (put) options represented as the current option value (delta adjusted exposure)

Currency exposure^{2,3} (%)



² Where possible, regions, countries and currencies classified on a look through basis.

Regional exposure^{1,2,3} (%)

Region	Long
North America	35.0
Western Europe	19.5
- Eurozone	13.7
- Rest Western Europe	3.5
- United Kingdom	2.2
Developed Asia	17.3
- Korea/Taiwan	11.9
- Japan	5.5
Developing Asia	14.2
- China/Hong Kong	11.9
- India	2.3
Australia	2.4
Total Equities	88.5
Other	0.5
Cash	11.0
Totals	100.0

Market cap exposure³ (%)

Band	Long
Mega (>\$100b)	44.2
Large (>\$25b <\$100b)	27.7
Medium (>\$5b <\$25b)	15.8
Small (<\$5b)	0.8

Investment Manager

- Global pragmatic value manager, long only and long-short
- Structured to reinforce alignment between investors and the investment team
- We attempt to take advantage of the market's tendency for irrational extrapolation, identify investments that offer a high margin of safety and build portfolios with a capital preservation focus

Fund features

- **Objective** – to achieve absolute returns in excess of the benchmark over the investment cycle (typically 3-5 years)
- **Global diversification** – Access to 30+ global companies via a single trade
- **Alignment of interests** – proportion of each team member's remuneration is invested into Antipodes funds. Antipodes also has a significant investment alongside unitholders
- **Simple access** – being exchange traded, investors can buy or sell AGX1 like a regular share during the trading day

Fund Ratings



Further information

- ☎ 1300 010 311
- ✉ invest@antipodespartners.com

Australia Head Office

Antipodes Partners Limited
Level 35, 60 Margaret St
Sydney NSW 2000
Australia

UK Office

Antipodes Partners Limited
6th Floor, Nova North
11 Bressenden Place
London SW1E 5BY UK

Disclaimer

The Zenith Investment Partners (ABN 27 103 132 672, AFS Licence 226872) ("Zenith") rating (assigned October 2020) referred to in this document is limited to "General Advice" (s766B Corporations Act 2001) for Wholesale clients only. This advice has been prepared without taking into account the objectives, financial situation or needs of any individual and is subject to change at any time without prior notice. It is not a specific recommendation to purchase, sell or hold the relevant product(s). Investors should seek independent financial advice before making an investment decision and should consider the appropriateness of this advice in light of their own objectives, financial situation and needs. Investors should obtain a copy of, and consider the PDS or offer document before making any decision and refer to the full Zenith Product Assessment available on the Zenith website. Past performance is not an indication of future performance. Zenith usually charges the product issuer, fund manager or related party to conduct Product Assessments. Full details regarding Zenith's methodology, ratings definitions and regulatory compliance are available on our Product Assessments and at <http://www.zenithpartners.com.au/RegulatoryGuidelines>

The Lonsec Ratings (assigned February 2020) presented in this document are published by Lonsec Research Pty Ltd ABN 11 151 658 561 AFSL 421445. The Ratings are limited to "General Advice" (as defined in the Corporations Act 2001 (Cth)) and based solely on consideration of the investment merits of the financial products. Past performance information is for illustrative purposes only and is not indicative of future performance. They are not a recommendation to purchase, sell or hold Antipodes products, and you should seek independent financial advice before investing in these products. The Ratings are subject to change without notice and Lonsec assumes no obligation to update the relevant documents following publication. Lonsec receives a fee from the Fund Manager for researching the products using comprehensive and objective criteria. For further information regarding Lonsec's Ratings methodology, please refer to our website at: <http://www.beyond.lonsec.com.au/research-solutions/our-ratings>.

Interests in the Antipodes Global Shares (Quoted Managed Fund) ARSN 625 560 269 ('Fund') are issued by Pinnacle Fund Services Limited, ABN 29 082 494 362, AFSL 238371. Antipodes Partners Limited ABN 29 602 042 035 AFSL 481580 ('Antipodes') is the investment manager of the Fund. The Product Disclosure Statement (PDS) for the Fund is available at www.antipodespartners.com.

Pinnacle Fund Services Limited is not licensed to provide financial product advice. Any potential investor should consider the current PDS in its entirety and consult their financial adviser before making an investment decision in relation to the Fund. Antipodes and Pinnacle Fund Services Limited believe the information contained in this communication is reliable, however no warranty is given as to its accuracy and persons relying on this information do so at their own risk. Any opinions or forecasts reflect the judgment and assumptions of Antipodes and its representatives on the basis of information at the date of publication and may later change without notice. The information is not intended as a securities recommendation or statement of opinion intended to influence a person or persons in making a decision in relation to investment. This communication is for general information only. It has been prepared without taking account of any person's objectives, financial situation or needs. Any persons relying on this information should obtain professional advice before doing so. Past performance is not a reliable indicator of future performance.

To the extent permitted by law, Antipodes and Pinnacle Fund Services Limited disclaim all liability to any person relying on the information in respect of any loss or damage (including consequential loss or damage) however caused, which may be suffered or arise directly or indirectly in respect of such information contained in this communication. Options exposure represents the market downside. For put options (typically used to limit potential downside) delta-adjusted exposure is used and for call options (typically used to capture potential upside) exposure is calculated using the current option value.